NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) recommendations for pacritinib (VONJO) as a myelofibrosis (MF) treatment1

INDICATION2: VONJO is indicated for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera [PPV] or 
post-essential thrombocythemia [PET]) MF with a platelet count below 50 x 109/L. This indication is approved under accelerated approval based on spleen volume reduction. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

The category 2A/2B recommendations below fall outside the Pacritnib (Vonjo) US prescribing information

NCCN Guidelines® select recommendations for pacritinib (VONJO)1*

Pacritinib (VONJO) is a recommended option in both first- and second-line by NCCN Guidelines.

Platelet counts <50 x 109/L higher-risk MF
Preferred
Platelet counts ≥50 x 109/L higher-risk MF
Recommended
MF-associated anemia
Recommended
  • First-line treatment option for patients with higher-risk MF who have platelet counts <50 x 109/L and are not candidates for transplant or for whom transplant is not currently feasible (Category 1, preferred)

 

  • First-line treatment option for patients with higher-risk symptomatic MF who have platelet counts ≥50 x 109/L and are not candidates for transplant or for whom transplant is not currently feasible (Category 2B)
  • Second-line treatment option for patients with higher-risk symptomatic MF who have platelet counts ≥50 x 109/L, are not candidates for transplant or for whom transplant is not currently feasible, and have no response or loss of response to initial treatment (Category 2B)

 

  • Treatment option for patients with MF-associated anemia who have no symptoms (Category 2B, other recommended regimen)
  • Treatment option for patients with symptomatic MF-associated anemia with symptoms not controlled (Category 2A, other recommended regimen)
  • Pacritinib as a treatment option in patients with symptomatic MF-associated anemia with symptoms currently controlled by a JAK inhibitor (Category 2A, useful in certain circumstances)
  • *See the NCCN Guidelines for detailed recommendations, including other options.
  • Symptomatic/symptoms=symptomatic splenomegaly and/or constitutional symptoms.
  • NCCN=National Comprehensive Cancer Network® (NCCN®).
  • References: 1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Myeloproliferative Neoplasms V.1.2024. © National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed December 21, 2023. To view the most recent and complete version of the guidelines, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way. 2. VONJO. Prescribing information. CTI BioPharma Corp.; 2023.